Bone remodeling depends on the precise coordination of bone resorption and subsequent bone formation. Disturbances of this process are associated with skeletal diseases, such as Camurati-Engelmann disease (CED). We show using in vitro and in vivo models that active TGF-b1 released during bone resorption coordinates bone formation by inducing migration of bone marrow stromal cells, also known as bone mesenchymal stem cells, to the bone resorptive sites and that this process is mediated through a SMAD signaling pathway. Analyzing mice carrying a CED-derived mutant TGFB1 (encoding TGF-b1), which show the typical progressive diaphyseal dysplasia seen in the human disease, we found high levels of active TGF-b1 in the bone marrow. Treatment with a TGF-b type I receptor inhibitor partially rescued the uncoupled bone remodeling and prevented the fractures. Thus, as TGFb1 functions to couple bone resorption and formation, modulation of TGF-b1 activity could be an effective treatment for bone remodeling diseases.
Bone remodeling depends on the precise coordination of bone resorption and subsequent bone formation. Disturbances of this process are associated with skeletal diseases, such as Camurati-Engelmann disease (CED). We show using in vitro and in vivo models that active TGF-b1 released during bone resorption coordinates bone formation by inducing migration of bone marrow stromal cells, also known as bone mesenchymal stem cells, to the bone resorptive sites and that this process is mediated through a SMAD signaling pathway. Analyzing mice carrying a CED-derived mutant TGFB1 (encoding TGF-b1), which show the typical progressive diaphyseal dysplasia seen in the human disease, we found high levels of active TGF-b1 in the bone marrow. Treatment with a TGF-b type I receptor inhibitor partially rescued the uncoupled bone remodeling and prevented the fractures. Thus, as TGFb1 functions to couple bone resorption and formation, modulation of TGF-b1 activity could be an effective treatment for bone remodeling diseases.
In the adult skeleton, bone is continuously being formed and resorbed, not only to maintain mineral homeostasis but also to cope with the microfractures that occur as a consequence of terrestrial life 1 . This bone remodeling process is accomplished by a precise coordination of the activities of two cell types: osteoblasts, which deposit the calcified bone matrix, and osteoclasts, which resorb bone 1 . Bone resorption and formation do not occur along the bone surface at random. Rather, they occur at specific anatomical sites and follow a well-defined sequence of events known as the bone remodeling cycle 2 . Disturbances of the bone remodeling process are often associated with skeletal diseases 1 , including CED, which is an inherited skeleton remodeling disorder characterized by a fusiform thickening of the diaphyses of the long bones and skull [3] [4] [5] .
Coupling of bone resorption and formation is believed to occur through release of a factor, or factors, from the bone matrix during osteoclastic bone resorption that directs migration of bone mesenchymal stem cells (BMSCs) to the bone resorptive surfaces [6] [7] [8] [9] [10] . The osteoclastic bone resorptive sites contain several soluble osteotropic factors, including transforming growth factor-b1 (TGF-b1) [11] [12] [13] , which is one of the most abundant cytokines in the bone matrix (200 mg kg -1 ) [13] [14] [15] . TGF-b1 is synthesized as a large precursor molecule, which is cleaved into active TGF-b1 and latency-associated protein (LAP). The LAP remains noncovalently linked to active TGF-b1, masking the receptor-binding domains of the TGF-b1 and rendering it inactive 16, 17 . TGF-b1 is thus secreted and deposited in the bone matrix as an inactive, latent complex 18, 19 . TGF-b1 has been shown to regulate proliferation and differentiation of osteoprogenitors, but the exact function of TGF-b1 in bone is unclear [20] [21] [22] [23] . Mapping of the chromosomal region associated with CED has identified TGFB1 as a candidate gene, and approximately ten different TGFB1 mutations have been identified in samples from families affected by CED 3, 4 . In 24 families with CED TGFB1 mutations, 22 individuals had been found to have a mutation located in the region encoding LAP; however, no mutations were found in the domain encoding the active TGF-b1 peptide 3, 4, 24 . Moreover, active TGF-b1 was readily released upon overexpression of the CED TGFB1 mutants in cultured cells 25, 26 .
BMSCs have been found to differentiate into a variety of cell types, including osteoblasts, chondrocytes and adipocytes, depending on the stimulatory microenvironment 27, 28 . BMSCs that are identified by the expression of 30) or CD146 (ref. 31 ) in humans and expression of CD29 and Sca-1 in mice 32, 33 have been characterized in terms of their potential for differentiation into osteoblasts and are widely used as experimental models of bone remodeling, fracture healing and bone regeneration, although there is no unique marker specific for the lineage of osteogenic BMSCs 27, 28, [34] [35] [36] [37] . Here we demonstrate that active TGF-b1 is released from the bone matrix in response to osteoclastic bone resorption and that this cytokine then induces migration of human and mouse osteogenic BMSCs in order to coordinate local rates of bone resorption with bone formation. We also show that this signaling by TGF-b1 in human and in mouse BMSCs occurs through SMAD-family signal-transduction proteins. Moreover, we have established a CED mouse model in which high levels of active TGF-b1 occur in the bone marrow microenvironment, as well as uncoupling of bone resorption and formation. Notably, treatment with a TGF-b type I receptor (TbRI) inhibitor partially rescued the bone remodeling defects in the CED mice. Thus, TGF-b1 functions as a primary factor for recruitment of BMSCs to the bone remodeling surfaces in the coupling process, and its dysregulation leads to disease.
RESULTS

TGF-b1 from bone resorption induces migration of BMSCs
We reasoned that the potential factor(s) should be released into the medium when mature and functional osteoclasts are cultured with bone slices in vitro and that the bone resorption-conditioned medium (BRCM) could then be tested for its effect on the migration of BMSCs. We first confirmed that on culture with macrophage colonystimulating factor and receptor activator of nuclear factor kappa B ligand (RANKL), monocytes or macrophages, which are osteoclast precursors, differentiated into osteoclasts that showed a multinuclear morphology, tartrate-resistant acid phosphatase (TRAP)-positive staining and bone resorption activity ( Supplementary  Fig. 1a ). In the absence of RANKL, the precursors did not differentiate into mature osteoclasts and did not show bone resorption activity ( Supplementary Fig. 1a) . We examined the effects of conditioned medium on the migration of STRO-1 + BMSCs ( Supplementary  Fig. 1b ) purified from human bone marrow using a Transwell assay in which the BMSCs were placed in the upper chamber and the conditioned medium was placed in the lower chamber (Supplementary Fig. 1c) . We found that the BRCM from mature osteoclasts cultured in the presence of bone slices induced significantly more cell migration (Fig. 1a) than the control conditioned medium from mature osteoclasts cultured without bone slices, confirming that factor(s) released during bone resorption can induce migration of BMSCs.
Many osteotropic factors are found in the bone matrix, including bone morphogenetic proteins (BMPs), platelet-derived growth factor (PDGF), and insulin-like growth factors I or II (IGF-I or IGF-II), as well as the TGF-bs 11, 18, 38 . The recombinant forms of these factors induce cell migration in vitro 10, 39 . We found that addition of an antibody specific for TGF-b1 to the BRCM significantly inhibited the migration of human STRO-1 + BMSCs, whereas antibodies specific for IGF-II or PDGF had a slight inhibitory effect, but the use of antibodies specific for TGF-b2, TGF-b3 or IGF-I or the use of noggin, a BMP antagonist, had no detectable effects (Fig. 1b) , indicating that TGF-b1 is a primary inducer of the migration of BMSCs in this assay.
High levels of active TGF-b1 were present in the conditioned medium from osteoclasts prepared in the presence of bone slices, as shown by ELISA (Fig. 1c) and western blot analysis (Fig. 1d) . Taken together with the finding that active TGF-b1 was barely detectable in other conditioned media (Fig. 1c,d ), although inactive latent TGF-b1 was present in the media (Fig. 1d) , these data suggest that osteoclastic bone resorption is critical for the activation of TGF-b1. Depletion of TGF-b1 in the BRCM by immunoprecipitation with an antibody to TGF-b1 significantly compromised the ability of the BRCM to induce cell migration, and readdition of TGF-b1 to the depleted medium restored its ability to induce cell migration in a concentrationdependent manner (Fig. 1e) . Moreover, BRCM prepared using osteoclasts generated from precursors obtained from normal mice cultured with bone slices obtained from Tgfb1 knockout (Tgfb1 -/-) mice, which contained barely detectable levels of active TGF-b1 (Fig. 1f) , was significantly less effective in inducing migration of BMSCs than BRCM obtained from osteoclasts cultured with wild-type (WT) bone (Fig. 1g) . However, the reduction of cell migration associated with the use of BRCM prepared from cells and bone from the Tgfb1 -/-mice was not as substantial as the inhibition observed when the TGF-b1-neutralizing antibody was added to the WT BRCM (Fig. 1b,g ), suggesting that in the absence of TGF-b1 expression, other factors may be present in higher-than-normal concentrations that partially support the migration of BMSCs in Tgfb1 -/-mice. Taken together, these results indicate that active TGF-b1 released during osteoclastic bone resorption induces migration of BMSCs, at least under the conditions of this assay.
TGF-b1 is essential for bone remodeling in adult mice
To determine the potential role of TGF-b1-induced migration of BMSCs in vivo, we used Tgfb1 -/-mice. TGF-b1 regulates proliferation of osteoprogenitors and inhibits differentiation of osteoblasts in vitro 21, 40 . Thus, while the skeletons of Tgfb1 -/-mice appear normal at 1 month of age (before death due to organ failure associated with autoimmune disease 41 ), the mice show depletion of preosteoblasts at the trabecular bone surfaces and the presence of osteoprogenitors in the middle of the bone marrow 42, 43 . However, to subsequently examine the potential involvement of TGF-b1 in the migration of BMSCs to the bone surface during bone remodeling in adult mice, we needed to prevent the autoimmune disease, thus extending the lives of the mice. This we achieved by crossing the Tgfb1 -/-mice with immunodeficient Rag2 -/-mice 44, 45 . Analysis of the 1-month-old Tgfb1 -/-Rag2 -/-mice confirmed that they did not show significant differences in trabecular bone volume, thickness or separation as measured by mCT ( Supplementary Fig. 2a-c) , whereas, compared to their WT littermates, the 3-month-old Tgfb1 -/-Rag2 -/-mice showed a significant loss of trabecular bone volume and thickness, and greater trabecular bone separation ( Fig. 2a-d ). Histologic staining of sections of the femur also indicated that the trabecular bone was irregular and notably reduced ( Fig. 2e and Supplementary Fig. 2d ). Moreover, bone histomorphometric analyses revealed significantly fewer osteoblasts but little difference in the numbers of osteoclasts in the 3-month-old Tgfb1 -/-Rag2 -/-mice as compared to their WT littermates (Fig. 2f,g ). Furthermore, immunostaining of femur sections demonstrated that Runx2-positive osteoblasts were missing on trabecular bone surface of the 3-month-old Tgfb1 -/-Rag2 -/-mice ( Fig. 2h) , suggesting a deficiency of osteoblasts on bone surfaces.
To examine the osteogenic potential of the BMSCs, whose misfunction may contribute to the bone loss in the adult Tgfb1 -/-Rag2 -/-mice, we plated suspensions of BMSCs isolated from the 3-month-old Tgfb1 -/-Rag2 -/-mice or their WT littermates at clonal density to obtain discrete colonies (colony forming unit-fibroblast (CFU-F)). The CFUFs were further induced in osteogenic medium and assessed for alkaline phosphatase activity (colony forming unit-osteoblast (CFU-Ob)) and for calcium deposition by alizarin red staining. The results indicated that the osteogenic potential of the BMSCs of the 3-month-old Tgfb1 -/-Rag2 -/-mice was equivalent to the osteogenic potential of the BMSCs of their WT littermates (Fig. 2i,j) . Considering that no bone defects are evident during prenatal development or the first month of postnatal growth of the Tgfb1 -/-mice, these results indicate a potential role for TGF-b1 in the migration of BMSCs to the bone surfaces and in the coupling process during bone remodeling in the adult mice.
TGF-b1 induces migration of BMSCs to the remodeling sites
To examine whether TGF-b1 induces migration of BMSCs to the bone remodeling surface in mice, we injected the osteogenic BMSCs into the femur cavity of the Tgfb1 +/+ Rag2 -/-and Tgfb1 -/-Rag2 -/-mice. As there is no unique marker for BMSCs, we isolated mouse CD29 + Sca-1 + CD45 -CD11b -BMSCs by fluorescence-activated cell sorting (FACS) from mouse BMSCs (Fig. 3a,b) . We then analyzed formation of CFUOb colonies as detected by alkaline phosphatase activity (Fig. 3c) , which confirmed that 95% of the sorted cells were osteogenic, and we further confirmed their osteogenic potential by von Kossa and alizarin red staining (Fig. 3d) . We also confirmed that the sorted BMSCs underwent BRCM-induced migration that was inhibited by the TbRI inhibitor (Fig. 3e) . The BMSCs were then labeled with GFP using a retrovirus and injected into the femur cavities of the Tgfb1 +/+ Rag2 -/-or Tgfb1 -/-Rag2 -/-mice (Fig. 3f) . The injected BMSCs were detected by immunostaining of the femur sections with an antibody specific for GFP 1 week or 4 weeks after injection (Fig. 3g) . In the Tgfb1 +/+ Rag2 -/-mice, the GFP-positive BMSCs were largely found at the trabecular bone surface 1 week after injection. At 4 weeks after injection, some of the GFP-positive BMSCs were embedded in the trabecular bone of these Tgfb1 +/+ Rag2 -/-mice, indicating osteoblastic differentiation of the injected BMSCs (Fig. 3g,h ). In the Tgfb1 -/-Rag2 -/-mice, in contrast, the GFP-positive BMSCs were dispersed in the bone marrow and very few of the BMSCs were found at the bone surface 1 week or 4 weeks after injection (Fig. 3g,h) . The mean value of the control group was set to zero. Scale bar, 50 mm. n ¼ 3. *P o 0.01. NS, not significant.
In a similar in vivo migration experiment, we injected human STRO-1 + CD45 -BMSCs into the cavity of the femur in the immunodeficient Tgfb1 +/+ Rag2 -/-and Tgfb1 -/-Rag2 -/-mice. The injected BMSCs were detected by immunostaining of sections of the femur with antibodies to human leukocyte antigen A (HLA-A) and RUNX2 to track migration and osteoblastic differentiation. In the Tgfb1 +/+ Rag2 -/-mice, the HLA-A-positive BMSCs were largely found at the trabecular bone surface and were RUNX2-negative 1 week after injection. At 2 weeks after injection, some of the injected human BMSCs at the trabecular bone surface in the Tgfb1 +/+ Rag2 -/-mice were RUNX2-positive. In contrast, the HLA-A-positive BMSCs were not found at the bone surfaces of the Tgfb1 -/-Rag2 -/-mice 1 week or 2 weeks after injection (Fig. 3i,j) . We obtained similar results (data not shown) with osteogenic CD146 + CD45 -human BMSCs isolated by FACS ( Supplementary Fig. 3a-c) . Taken together, these results indicate that TGF-b1 is essential for the migration of BMSCs to the bone surfaces.
SMAD signaling mediates TGF-b1-induced migration of BMSCs
We then examined the signaling pathway(s) that mediate TGF-b1-induced migration of BMSCs. It is well established that phosphorylation of receptor-regulated SMADs (R-SMADs) by TbRI is the primary TGF-b signaling pathway 46, 47 . We found that a TbRI kinase-specific inhibitor (SB-505124) 48 blocked the BRCM-induced migration of BMSCs in a concentration-dependent manner (Fig. 4a) and that retrovirus-mediated expression of SMAD7 inhibited the migration of the BMSCs (Fig. 4b) , which further indicates that TGF-b1 is acting through TbRI to induce migration of the BMSCs because SMAD7 is known to bind specifically to TbRI and inhibit phosphorylation of SMAD2 and SMAD3 (ref. 49 ). Moreover, retrovirus-mediated expression of a constitutively active TbRI in BMSCs was as effective in inducing the migration of the BMSCs as the addition of purified human TGF-b1 in a scratch assay (Supplementary Fig. 3d ). Collectively, these data indicate that the TGF-b1-induced migration of BMSCs is mediated through TbRI signaling.
To examine the role in TGF-b1-induced BMSC migration of the known activating SMADs that are downstream of TbRI, SMAD2 and SMAD3, we reduced the expression of endogenous SMAD2 or SMAD3 or both using short interfering RNAs (siRNAs) (Fig. 4c) . Significant inhibition of BRCM-mediated cell migration was not observed on treatment with SMAD2 siRNA alone (Fig. 4c) . Significant inhibition was observed when the cells were treated with SMAD3 siRNA alone and even greater inhibition was observed when the cells were treated with both siRNAs (Fig. 4c) , suggesting that SMAD3 is Tgfb1 primarily responsible for TGF-b1-induced migration of BMSCs and its function can be partially compensated by SMAD2. As the phosphorylated R-SMADs form a functional complex with SMAD4, the common signal transducer for all R-SMADs 46 , we also examined the effect of deletion of endogenous Smad4 in primary mouse BMSCs on TGFb1-induced cell migration. BMSCs isolated from mice carrying a loxP-flanked Smad transgene (Smad4 lox/lox mice) 50 were infected with adenovirus bearing either Cre recombinase or GFP and the endogenous Smad4 gene was deleted (Fig. 4d) . BMSCs isolated from the mice with deletion of Smad4 showed reduced BRCM-induced migration (Fig. 4d) . Thus, SMAD signaling is essential for the TGF-b1-induced migration of BMSCs. During migration, cells show characteristic lamellipodia-like protrusions that can be identified by staining with phalloidin. To examine the effects of SMAD signaling on the cytoskeleton, we used a model in which cell morphology can be examined as the BMSCs migrate in a TGF-b1 gradient. The BMSCs showed directed migration within the TGF-b1 gradient ( Supplementary Fig. 3e,f) , quantified as the number of BMSCs that migrated in the direction of increasing TGF-b1. In the absence of the gradient, the cells showed little migration, and its direction was random ( Supplementary Fig. 3e,f) . BMSCs that were migrating toward a gradient showed typical lamellipodia-like protrusions ( Supplementary  Fig. 3g,h ). Addition of TbRI inhibitor was associated with formation of fewer protrusions, whereas the formation of stress fibers was not affected. Similar results were obtained upon deletion of Smad4 in primary BMSCs ( Supplementary Fig. 3g,h) , suggesting that the SMAD signaling pathway is required for the formation of the lamellipodia-like protrusions required for TGF-b1-induced cell migration.
To examine the effect of interrupting TGF-b signaling and the TGFb gradient on cell migration in vivo, GFP-labeled BMSCs were injected along with the TbRI inhibitor, active exogenous TGF-b1 or vehicle into the femoral cavities as described above, and detected by immunostaining with a GFP antibody. In the vehicle treatment group (Fig. 4e,f) , the BMSCs were largely found at the bone remodeling sites defined by the presence of TRAP-positive mature osteoclasts. Co-injection of TbRI inhibitor reduced the numbers of BMSCs at the active remodeling surfaces (Fig. 4e,f) . Moreover, co-injection of active exogenous TGF-b1 to disrupt the TGF-b1 gradient in bone also significantly reduced the BMSCs at the active remodeling surfaces (Fig. 4e,f) . These results indicate that SMAD signaling mediates the TGF-b1-induced migration of BMSCs and that interruption of TGF-b signaling and the TGF-b1 gradient reduces the recruitment of BMSCs to bone remodeling surfaces.
Excess TGF-b1 activity explains the CED phenotype in mice To examine the effects of the CED TGFB1 point mutations in the LAP region on TGF-b1 activity, we generated expression constructs for WT TGFB1 and for five TGFB1 point mutations that have been previously identified in subjects with CED . After transfection of these constructs into 293T cells, we collected conditioned media and found that all the samples contained the inactive latent form of TGF-b1; however, the conditioned media from the cells expressing mutant TGFB1 contained much greater amounts of active TGF-b1 than the conditioned media from cells expressing WT TGFB1 (Fig. 5a) . We also found that the ratio of active to total TGF-b1 in the conditioned media from the cells expressing the mutant TGFB1 was significantly higher (Supplementary Fig. 4a ) and that the conditioned media from the cells expressing mutant TGFB1 were hyperactive in inducing the migration of human STRO-1 + BMSCs (Fig. 5b) . Thus, expression of the CED-derived TGFB1 mutants was associated with significantly enhanced formation of active TGF-b1.
To examine the effects of this enhanced formation of active TGF-b1 on bone formation, we generated two osteoblast tissue-specific transgenic mouse models, one with a CED-derived TGFB1 mutation (H222D) and one with WT TGFB1 as a control, in which the expression was driven by a 2.3-kb type I collagen promoter (Supplementary Fig. 4b) . In both transgenic mice, we obtained two lines. The expression levels and their bone phenotypes were very similar between two founders of the same transgene. We confirmed the specific expression of the transgenes in bone tissue (Supplementary Fig. 4c ). Notably, the amounts of total or latent TGF-b1 in the bone marrow were significantly greater in both CED-and WT-TGFB1 transgenic mice than in their WT littermates ( Supplementary Fig. 4d,e) , whereas the amounts of active TGF-b1 in the bone marrow of CED mutant mice were much greater than in the WT-TGFB1 transgenic mice or their WT littermates ( Fig. 5c and Supplementary Fig. 4d ), indicating premature release of active TGF-b1 in CED mice. There were no detectable defects in the skeletons of neonatal CED mice (Fig. 5d) . Diaphyseal thickening was initially observed as is characteristic of human CED, explaining its alternative name, progressive diaphyseal dysplasia. We observed this typical thickening in the lower limbs of 1-month-old CED mice (Fig. 5d,e) . The main defects we found in the CED mice affected the long bones. More than 50% of mice had tibial fractures by 3 months of age (Fig. 5d) . Thus, enhanced formation of TGF-b1 in the bone marrow in these mice seems to be associated with defective bone remodeling that primarily affects the long bones. The major bone defects in the long bones of the CED mice are similar to that seen in humans with CED. Such defects were not observed in either WT-TGFB1 transgenic mice or WT littermates, although the total bone volumes did not differ among any of these genotypes (Fig. 5f,g ). Consecutive measurements of bone volume in cross-sections 0.5 mm thick along the length of the tibia by microcomputed tomography (mCT) demonstrated a fluctuating bone volume in the CED mice (Fig. 5h) . Bone histomorphometric analysis of the tibia provided insights into the basis for this fluctuating bone volume. As in humans with CED, the cortical thickness was increased about fourfold relative to WT-TGFB1 transgenic mice or WT littermates. The bone porosity, osteoblast surface and osteoclast surface in cortical bone (that is, the relative surface areas of cortical bone covered by osteoblasts and osteoclasts, respectively) were also significantly higher in CED mice, indicating high bone turnover and abnormal bone remodeling (Supplementary Table 1 ). Moreover, the osteoclasts and osteoblasts were clustered in separated areas (Fig. 5i) , indicating uncoupled bone resorption and formation. Because the CED mutant TGFB1 was specifically expressed in the cells of osteoblastic lineages, the clustering of the osteoblasts is likely to be due to the high levels of active TGF-b1 secreted from the osteoblastic cells, which may induce migration of BMSCs in this microenvironment and stimulate their proliferation. In parallel, the availability of BMSCs to bone resorptive sites is limited because the active TGF-b1 released from the osteoblastic cells draws the BMSCs away from the resorption pits. Thus, osteoclastic bone resorption continues but without concomitant bone formation during remodeling cycles. In addition, the secretion of active TGF-b1 from the osteoblastic cells most likely blunts the TGF-b1 gradient created by osteoclastic bone resorption, as suggested by the ability of injection of exogenous TGF-b1 into the bone cavity to interfere with the recruitment of BMSCs to bone remodeling sites (Fig. 4e,f) . Indeed, cells labeled by an antibody specific for phosphorylated Smad2 and Smad3 (phospho-Smad2/3) were significantly more abundant in the areas of clustered osteoblasts in CED mice, indicating high levels of active TGF-b1. These effects were not seen in the WT-TGFB1 transgenic mice ( Supplementary Fig. 5a ). Upon 5-bromodeoxyuridine (BrdU) labeling, more BrdU-labeled cells were observed in the CED mice ( Supplementary Fig. 5b ). Most importantly, the cells positive for Total BV/TV (%)
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Active TGF-β1 (ng ml both phospho-Smad2/3 and BrdU were found in the vicinity of osteoclastic bone resorption surfaces in the WT-TGFB1 transgenic mice or their littermates, whereas few of these positive cells were found at the bone resorption sites in the CED mice ( Supplementary  Fig. 5a ,b). These in vivo results indicate that secretion of high levels of active TGF-b1 by the osteoblastic cells in CED mice provided a microenvironment that resulted in the formation of clusters of osteoblastic cells and prohibited migration of the BMSCs to bone resorption sites.
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TbRI inhibitor rescues bone remodeling defects in CED mice
If enhanced formation of active TGF-b1 in the bone marrow microenvironment uncouples bone resorption and formation in CED mice, inhibition of TGF-b1 activity in the bone marrow may be capable of preventing the bone remodeling defects in CED mice. To test this possibility, we injected CED mice intraperitoneally with different concentrations of TbRI inhibitor or vehicle every day for 7 weeks. Analysis of long bone structures by X-ray and mCT showed that injection of TbRI inhibitor resulted in improvements in the bone morphology and the distribution of bone mass. These effects were dependent on the concentration of the injected TbRI inhibitor (Fig. 6a,b) . Tibial fractures were largely prevented in treated CED mice, whereas more than 50% of fractures were still observed in the vehicle control group (Fig. 6a) . Moreover, consecutive measurements of cross-sections of bone volume by mCT along the longitude of the tibia showed that the bone volume was more evenly distributed after TbRI inhibitor treatment (Fig. 6c) , indicating partial rescue of bone remodeling defects. Notably, the total bone volumes were not altered on treatment with the TbRI inhibitor ( Fig. 6b and Supplementary Fig. 6a-c) . Bone histomorphometric analysis showed that the CED mice treated with TbRI inhibitor had significantly less cortical thickness, porosity, osteoblast surface and osteoclast surface, indicating restoration of normal bone remodeling in CED mice (Supplementary Table 1 ).
Immunostaining of the tibial sections demonstrated that in the CED mice treated with TbRI inhibitor osteocalcin-positive osteoblasts and TRAP-positive osteoclasts were associated on the bone surface. This was in marked contrast to the clustering of the osteoclastic cells and osteoblasts in separated areas in the vehicle-treated CED mice (Fig. 6d) . Indeed, there were fewer cells positive for either phosphoSmad2/3-or BrdU in the tibial sections of the CED mice treated with TbRI inhibitor, and these cells were dispersed and associated with TRAP-positive osteoclasts ( Supplementary Fig. 6d,e) . Inhibition of the formation of osteoblastic cell clusters by the TbRI inhibitor may lead to a more even distribution of the BMSCs, rendering them available to respond to the local TGF-b1 signal generated by osteoclastic bone resorption and thereby promoting the coupling of bone formation and resorption. Taken together, these results indicate that uncoupled bone resorption and formation can be partially rescued by inhibiting the abnormally high TGF-b1 activity in the bone microenvironment of CED mice.
DISCUSSION
The published data regarding the exact function of TGF-b1 in bone are seemingly ambiguous 20 . Although TGF-b1 has been shown to stimulate proliferation of progenitors and inhibit osteoblast differentiation of the osteoprogenitors in cell cultures and transgenic mouse models 20 , the skeleton of Tgfb1 -/-mice appears normal at 3 weeks of age, and there are no reports of defects during prenatal skeletal development or perinatal bone growth in these mice 42, 43 . Analysis of older Tgfb1 -/-mice has been hindered by their early death due to the associated autoimmune disease 41 . The use of immunodeficient Tgfb1 -/-Rag2 -/-mice has allowed the analysis of older mice, and this has revealed that these mice do show substantial bone defects at 3 months of age. This implies that TGF-b1 does play a critical role in bone formation and further suggests that TGF-b1 plays a role in bone remodeling in adult mice.
TGF-b1-directed migration of BMSCs to resorptive sites is an essential step in the coupling process. The BMSCs then undergo osteoblastic differentiation in response to the signals provided by the microenvironment of the resorptive sites. To track the migration of osteogenic BMSCs in vivo, we used both human osteogenic BMSCs sorted by STRO-1 or CD146 and mouse osteogenic BMSCs sorted by Sca-1, CD29, CD45 and CD11b, as there is no unique marker for osteogenic BMSCs. We found that TGF-b1 induced migration of BMSCs to the bone surfaces where osteoblast differentiation was induced. Both the physical properties of the fresh resorption site and soluble factors are likely to contribute to the differentiation of BMSCs. At fresh resorptive sites, the bone mineral matrix is exposed and lacks a covering of lining cells, providing a stiff, elastic microenvironment that can direct differentiation of BMSCs 51 . The exposed bone is also rich in osteotropic factors, including BMPs, IGF-I, IGF-II and PDGF, which promote differentiation of BMSCs into osteoblasts. In the absence of directed migration and attachment to the freshly exposed bone remodeling surface, the BMSCs are unlikely to differentiate into osteoblasts effectively. This may contribute, in part, to bone loss at the sites of resorption specifically and, perhaps, to a more generalized bone loss in the Tgfb1 -/-mice. Alterations in bone remodeling are often associated with bone diseases, including CED, hyperparathyroidism, Paget's disease, multiple myeloma, osteoporosis and osteopetrosis 1 . The association of point mutations in the TGFB1 LAP region with CED provides an ideal in vivo model to validate the role of TGF-b1 in coupling bone resorption and formation. Introduction of a CED TGFB1 point mutation resulted in significant bone remodeling defects in these transgenic mice, although their total bone volumes did not differ significantly from that of their WT littermates. The levels of total and latent TGF-b1 were high in both the CED-and WT-TGFB1 transgenic mice, whereas the CED mice differed from their WT littermates and WT control transgenic mice in that they expressed high levels of active TGF-b1 in the bone marrow microenvironment, like humans with CED. Because the TGFB1 bearing the CED point mutation is overexpressed in CED mice, the amount of active TGF-b1 is likely to be greater than that in CED patients. Nonetheless, these in vivo observations provide further evidence that active TGF-b1 plays a primary role in coupling bone resorption and formation in adult mice.
The available strategies for the treatment of osteoporosis are based on either specific inhibition of osteoclast activity or stimulation of osteoblast activity, and their effectiveness is compromised by the attempts of the internal coupling mechanism to balance bone resorption and formation 1 . Our results suggest new types of approaches for antiosteoporosis therapy based on direct targeting of the balance between bone resorption and formation. Likewise, the adult skeleton undergoes constant remodeling, and many diseases of the bone are associated with defects in the coupling process. In primary hyperparathyroidism, hyperthyroidism and Paget's disease, there is excess bone formation after each cycle of osteoclastic bone resorption during remodeling [52] [53] [54] . Our results suggest that targeting of TGF-b1 signaling could potentially prove to be an effective therapy for these disorders.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
